Business
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica’s investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, DiaMedica will be looking for improvements in uterine artery dilation, indicating that DM199 therapy is potentially disease modifying in these patients.\n\n\n“We are extremely excited to announce the dosing of the first patient in the PE trial,” said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. “This is a significant milestone for the entire medical community focused on improving maternal and fetal health. Preeclampsia is a serious condition, and we are eager to assess the potential of DM199 to provide a much needed therapy for PE sufferers.”\n\n\nDr. Lorianne Masuoka, DiaMedica Therapeutics’ Chief Medical Officer, added, \"This moment represents a crucial step forward in our mission to provide a safe and effective treatment for preeclampsia and is a testament to our team’s dedication and commitment. We are proud of this progress and remain focused on achieving our clinical goals.\"\n\n\nAbout Preeclampsia\n\n\nPreeclampsia is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of stroke, placental abruption, progression to eclampsia, premature delivery, and death. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke. There are currently no approved therapeuti...